ArticlePsychopharmacology2026
Intranasal vasopressin, but not oxytocin, decreases ethanol intake in socially housed mice.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Intranasal Vasopressin Decreases Voluntary Ethanol Drinking in Single- and Group-Housed Mice Through Mechanisms Involving Vasopressin 1a and 1b Receptors.Alcohol, clinical & experimental research · 2026Article
- Intranasal Drug Delivery in Neuropharmacology: Advances in Brain-Targeted Therapies and Bioethical Challenges.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
rationaleOxytocin decreases alcohol consumption across a variety of non-human animal models. However, clinical trials using this peptide have produced mixed results. Among the reasons for difficulties in translating preclinical findings of promising treatments for alcohol use disorder to clinical applications is that many non-human animal studies do not sufficiently model the human conditions.
objectivesThe current study used the translationally relevant intranasal route of administration of peptides and social housing to test the effects of oxytocin (Oxt) and arginine vasopressin (AVP) on voluntary alcohol drinking in mice.
methodsAll experiments used male and female C57BL/6J mice drinking alcohol or sweetened alcohol and water in a 2-bottle choice procedure. Intranasal Oxt (3 mg/kg) was administered to single-housed mice. Intranasal Oxt (3 mg/kg) or AVP (3 or 1 mg/kg) were administered to group-housed mice.
resultsIntranasal Oxt decreased alcohol intake in single housed mice, but was ineffective in decreasing drinking of alcohol or sweetened alcohol in group-housed mice. In contrast to Oxt, AVP decreased consumption of sweetened alcohol in group-housed mice. This effect was blocked by AVP receptor 1a antagonist and was non-selective to alcohol at higher (decreased sucrose consumption), but not lower, doses of AVP.
conclusionsOur studies for the first time demonstrate that Oxt loses its effectiveness when administered to rodents in translationally relevant conditions (intranasal route and social housing), which could reflect its limited success in clinical trials. In addition, they suggest that intranasal AVP could be more effective than Oxt in decreasing alcohol intake in these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.